Project: Metabolic Therapy for Managing Diastolic Heart Failure
| Acronym | MINOTAUR (Reference Number: 3. JTC-2016_028) |
| Duration | 01/05/2017 - 30/04/2020 |
| Project Topic | Every fifth person aged >65 years is at increased risk to develop diastolic heart failure essentially due to metabolic disorders, such as obesity or Diabetes Mellitus Type 2. No treatment has yet been shown to convincingly target and prevent diastolic heart failure. The MINOTAUR consortium will test whether caloric restriction-like acting compounds (also known as caloric restriction mimetics) prevent the development of diastolic dysfunction and improve diastolic function in a clinically relevant experimental model of diastolic heart failure, and taking into consideration gender aspect. Unraveling the molecular details of the disease can lead to nutrition–based personalized therapy (i.e., functional food-based nutritional regimes) as a novel and innovative protective and/or therapeutic approach that will likely result in fewer hospitalizations and promote healthy (cardiac) aging in future. |
| Network | ERA-CVD |
| Call | ERA-CVD Joint Transnational Call 2016 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Medical University of Graz | Coordinator | Austria |
| 2 | Ruhr University Bochum | Partner | Germany |
| 3 | Faculty of Medicine, University of Porto | Partner | Portugal |
| 4 | French Institute of Health and Medical Research (INSERM-Paris 6) | Partner | France |
| 5 | National Institute of Cardiovascular Research (CNIC) | Partner | Spain |